Lisata Therapeutics has filed a lawsuit against Kuva Labs and its subsidiary Kuva Acquisition Corp following the termination of their merger agreement. The clinical-stage pharmaceutical company alleges Kuva breached the agreement dated March 6, 2026, and is seeking damages for stockholders plus a $2 million termination fee. Lisata’s board is evaluating strategic alternatives including a potential acquisition, merger, reverse merger, asset sales, or liquidation. To preserve cash, the company reduced its workforce by approximately 72%, including the executive vice president of research and development and chief medical officer role.
Lisata Therapeutics Inc.Lisata sues Kuva for breach of merger agreement, seeking damages and termination fee, while cutting workforce by 72%.
Kuva is sued for alleged breach of merger agreement, facing damages and termination fee.